Mymetics Corp (MYMX)

[INTEGRITY STOCKS]

TOP REASONS TO BUY MYMX NOW! -July 17th 2017

The #1 BIOTECH Stock to BUY right now
Bill Gates is backing this amazing unknown biotech
Their technology has already been proven to eliminate the World's deadliest diseases!
Mymetics Corp. (MYMX)





Mymetics Corp (MYMX) is THE most undervalued Biotech stock EVER and our #1 Pick for the stock to buy right now!
Financially backed by The Bill and Linda Gates Foundation, The European Union and The Swiss government, Mymetics Corp (MYMX) is a MEGA stock in the making!
Do not get left behind, trading under a nickel a share and under the radar now is the time to buy shares of Mymetics Corp (MYMX), it's amazing cutting edge new virosome vaccine technology has already been proven to eliminate the World's deadliest diseases!

Mymetics Corp (MYMX)
The Biotech Changing The World



Highlights:
-Cutting edge revolutionary Virosome vaccine technology will change the World!
-Extremely undervalued trading under a nickel, will become a dollar stock
-European Union and Swiss government funding work
-Bill and Linda Gates Foundation funding research and trials (AWESOME what other penny stock can say that!)
-Will upgrade to NASDAQ
-Share structure: 303M O/S, Float of 98M -share structure unchanged for 5 years
-No dilution
-Advanced trials already working with Big Pharma Sanofi, in discussions with others
-#1 Ranked Biotech for 2017 most likely to be acquired by Big Pharma
-Owns the proprietary technology used in it's Virosome vaccine process
-Global leader in Virosome based vaccine
-Five Virosome vaccines in pipeline, results have been "SPECTACULAR"
-Respected Independent investment research group MORNINGSTAR give it 3 stars TOP rating!

DRUG PIPELINE

HIV/AIDS

Mymetics Corp (MYMX) is the Global leader in new revolutionary virosome based vaccines. Their HIV virosome vaccine has proven in clinical trials to be 100% effective in preventing HIV in primates, limited Human trials have yielded near perfect best ever results and Mymetics Corp (MYMX) says Big Pharma partnerships are under discussion!

But that is just the tip of the iceberg check this out:
Intra-Nasal Influenza (flu)

Mymetics Corp (MYMX) virosome intra nasal Influenza (FLU) vaccine has shown awesome success in Phase 1 clinical trials and exceeded all European Medicines Agency criteria, imagine a cure for the FLU, no more common colds!
Mymetics Corp (MYMX) has announced that Big Pharma Sanofi (SNY) is now working together with them on their virosome intra nasal Influenza (FLU) vaccine AND that this could result in a further and more extensive collaboration between the two companies.


BUT IT GETS EVEN BETTER:
RSV
Mymetics Corp (MYMX) RSV virosome vaccine to fight this respiratory pathogen in chronic pulmonary or cardiovascular disease has proven 100% effective in mice and cotton rats against a live virus challenge. The company has already a $5 million as an upfront cash payment for it's RSC virosome vaccine and is evaluating a new Big Pharma offer believed to be Pfizer (PFE)


Malaria
In trials conducted by The National Institute of Allergy and Infectious Diseases Mymetics Corp (MYMX) virosome vaccine for Malaria demonstrated a reduction of (97-100%) of the transmission of the parasite. Incredible!! Here too the company is evaluating potential partnerships! They are working with the Swiss Public Health, an institute at University of Basel. The University of Basel has a partnership with Big Pharma Roche in the form of partial project funding, in-kind contributions and access to Roche know-how. In return, Roche has the first right of negotiation for the commercial application of research results.


Chikungunya ( Dengue, Zika and Yellow fever)

Mymetics Corp (MYMX) announced that they are just beginning work on preclinical studies to develop a virosome vaccine for the Chikungunya virus (CHIKV) which is transmitted by several species of mosquitoes, which are also known to transmit Dengue, Zika and Yellow fever. The incredible effectiveness of their cutting edge virosome vaccine technology will undoubtedly prove successful here as well!

Partnerships and Funding

Mymetics Corp (MYMX) has some amazing partners backing them, in fact they have been so well funded there share structure has remained unchanged for FIVE years with no dilution to shareholders! What other small biotech can say that:
Just look at the money backing Mymetics Corp (MYMX):



MORE ABOUT Mymetics Corp (MYMX)
INCREDIBLE BREAKTHROUGH Virosome Vaccines


















With over 34 million victims, HIV/AIDS is the fourth cause of mortality worldwide, and the leading cause of death in sub-Saharan Africa. In 2014, the number of people living with HIV was estimated at 37 million. That same year 2.0 million new people were infected with the virus and 1.2 million deaths were caused by HIV (source: WHO).
TARGET POPULATION AND MARKET SIZE

The target population for Mymetics prophylactic HIV vaccine candidate is the global population, which provides another major block-buster opportunity in developed countries.
MYMETICS’ HIV/AIDS PREVENTIVE VACCINE APPROACH

Most HIV infections are sexually transmitted1 through direct contact of an infected mucosal membrane. Therefore, mucosal tissues represent the primary HIV entry door, as for many other pathogens.
Mymetics’ vaccine targets earlier transmission and infection events that take place at the mucosal level during the first minutes or hours following exposure to HIV.

Observations made on certain persons that are naturally resistant to HIV-12 infection revealed that despite their exposure to multiple HIV-1 positive individuals, they remain HIV-1 negative. This natural resistance is linked to the presence of mucosal antibodies against the HIV-1 present in their vaginal secretions. Similar resistance was also noted in males3.

By using an influenza virosome and specifically designed antigens Mymetics’ aim is to transpose the mucosal antibody response in the vaccine design, therefore reproducing Mother Nature. Our preventive HIV-1 vaccine formulation triggers not only blood antibodies but also mucosal antibodies, whereas all the other vaccine candidates are aimed only at the production of blood antibodies.

As a result, Mymetics' virosome based vaccine stimulates a defence mechanism effectively blocking entry of the virus at the mucosal level, the gateway of human infections.



RSV is a respiratory pathogen which infects patients of all ages. The infection can be especially severe in infants and older adults with chronic pulmonary or cardiovascular disease. Each year the virus infects 64 million people and is responsible for 160,000 deaths worldwide. Currently, there is no vaccine available for this highly contagious virus.
TARGET POPULATION AND MARKET SIZE
Mymetics RSV vaccine candidate is targeting the elderly population, representing a target population in the Western world of about 150 million. The potential RSV vaccine sales is estimated between USD 1. 2 and USD 1.5 billion USD a year and is thereby one of the few remaining vaccines with block-buster potential.
MYMETICS’ RSV VACCINE APPROACH

The virosome is produced from the RSV virus, by dissolving the RSV membrane, taking out the genetic material and reconstituting the lipid membrane including the natural RSV proteins.
ENCOURAGING RESULTS

In pre-clinical studies Mymetics’ vaccine has shown strong safety and immunogenicity and the vaccine did not induce enhanced disease, while mice and cotton rats were completely protected against a live virus challenge.



According to the WHO, there were an estimated 207 million cases of malaria in 2012 and an estimated 627 000 deaths of which 482 000 children under five years of age. 90% of all malaria deaths occur in sub-Saharan Africa. That is 1300 children every day, or one child almost every minute.
If not treated, malaria can quickly become life-threatening. In many parts of the world, the parasites have developed resistance to a number of malaria drugs. Malaria being an extremely climate-sensitive disease, a potential risk exists that Global Warming leads Malaria towards areas in higher latitudes.1
MYMETICS' MALARIA VACCINE APPROACH

The parasite has two main stages of development, implying that the surface of the parasite (sporozoites or merozoites) are constantly changing. Accordingly, the ideal vaccine should target different proteins from the various stages to improve the chance of obtaining protection or reducing the symptoms related mostly to the red blood cell infection.
The first malaria vaccine candidate is using the influenza virosome as the carrier and adjuvant with the incorporation of several antigens that target the two forms of the parasite and is thereby one of the few vaccine developed with this approach.
The second malaria vaccine candidate is a transmission blocking vaccine which also uses the Mymetics virosome technology by incorporating two transmission blocking antigens from the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the NIAID.
The transmission-blocking vaccine candidate seek to interrupt the life cycle of the parasite by inducing antibodies that prevent the parasite from maturing in the mosquito after it takes a blood meal from a vaccinated person. A successful transmission-blocking vaccine would be expected to reduce deaths and illness related to malaria in at-risk communities.
TARGET POPULATION AND MARKET SIZE

Both these vaccine candidates are primarily targeted to the overall population in sub-Saharan Africa and as a traveller vaccine. The market size for a malaria vaccine is estimated at USD 400 to USD 600 million.



Influenza, commonly referred as flu, is a contagious respiratory illness caused by influenza viruses. It rapidly spreads around the world in seasonal epidemics and imposes a considerable economic burden in the form of hospital and other health care costs and lost productivity. In annual influenza epidemics, 5-15% of the population is affected with upper respiratory tract infections. Worldwide, these annual epidemics result in about three to five million cases of severe illness, and about 250 000 to 500 000 deaths (source WHO).
MYMETICS’ INFLUENZA VACCINE APPROACH

Our influenza vaccine is based on virosomes that do not contain a “live virus”. The vaccine, being administered in the nose, can therefore fight the virus at the mucosal level by developing not only mucosal antibodies but also blood antibodies. Consequently, the infection is stopped at the point of entry and prevents even the earliest onset of disease.
TARGET POPULATION AND MARKET SIZE

The seasonal flu market has reached close to USD 3 billion in 2012 and is expected to grow at a CAGR of 3.2%. The intra-nasal application is expected to take market share from the injected vaccines due to ease of use and efficacy.



Chikungunya virus (CHIKV) is transmitted by several species of mosquitos, which are also known to transmit Dengue, Zika and Yellow fever. Symptoms include joint pain, swelling and stiffness of joints, nausea, fever, fatigue and head ache. Arthritis is the most common direct consequence of infection. The virus has spread from Africa, Asia and Islands in the Pacific and Indian Ocean to Southern Europe, the Americas and the Caribbean.
There currently is no vaccine against Chickungunya infection.
MYMETICS' CHIKUNGUNYA VACCINE APPROACH

Mymetics is developing a preventive CHIKV vaccine consisting of an enveloped virus like particle (virosome) which contains the most import antigens and a possibility to include an adjuvant.
LATEST RESULTS AND NEXT STEPS

We are currently at the end of the discovery program which has mainly focused on production, yield and feasibility. In the second half of 2017 we plan to enter into preclinical studies.